Circulating microRNAs are related to cognitive domains in the general population

preprint OA: closed
📄 Open PDF Full text JSON View at publisher
AI-generated summary by claude@2026-07, 2026-07-15

This study found 15 circulating microRNAs associated with cognitive domains, seven of which also related to cortical thickness and two to hippocampal volume in a general population cohort.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-07, 2026-07-15 · read from full text

This population-based study measured circulating microRNAs and microRNA co-expression clusters in 2869 participants to test associations with cognitive domains, structural MRI measures, and target gene expression. It found five previously reported and ten novel microRNAs linked to cognitive domains, with seven also associated with cortical thickness and two with hippocampal volume; functional genomics analyses suggested these microRNAs regulate genes in pathways including neurogenesis, axon guidance, and synapse assembly. A key caveat stated in the paper’s framing is that replication and broader identification of such microRNAs had been lacking, implying the work addresses this gap but remains observational in design as described (no interventional or causal validation is provided in the abstract). The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

ABSTRACT INTRODUCTION Circulating microRNAs have been suggested as candidates for detecting and preventing subclinical cognitive dysfunction. However, replication of previous findings and identification of novel microRNAs associated with cognitive domains, including their relation to brain structure and the pathways they regulate, are still lacking. METHODS We examined circulating microRNAs and microRNA co-expression clusters in relation to cognitive domains, structural MRI measures, and target gene expression in 2869 participants of a population-based cohort. RESULTS Five previously identified and 10 novel microRNAs were associated with cognitive domains. Importantly, seven of these microRNAs were also associated with cortical thickness and two with hippocampal volume. Functional genomics analysis showed that the identified microRNAs regulated genes in pathways like neurogenesis, axon guidance, and synapse assembly. DISCUSSION We identified microRNAs associated with cognitive domains, brain regions, and neuronal processes affected by aging and neurodegeneration, making them promising candidate blood-based biomarkers or therapeutic targets of subclinical cognitive dysfunction.
Full text 4,135 characters · extracted from oa-doi-fallback · 4 sections · click to expand

Abstract

INTRODUCTION Circulating microRNAs have been suggested as candidates for detecting and preventing subclinical cognitive dysfunction. However, replication of previous findings and identification of novel microRNAs associated with cognitive domains, including their relation to brain structure and the pathways they regulate, are still lacking.

Methods

We examined circulating microRNAs and microRNA co-expression clusters in relation to cognitive domains, structural MRI measures, and target gene expression in 2869 participants of a population-based cohort.

Results

Five previously identified and 10 novel microRNAs were associated with cognitive domains. Importantly, seven of these microRNAs were also associated with cortical thickness and two with hippocampal volume. Functional genomics analysis showed that the identified microRNAs regulated genes in pathways like neurogenesis, axon guidance, and synapse assembly.

Discussion

We identified microRNAs associated with cognitive domains, brain regions, and neuronal processes affected by aging and neurodegeneration, making them promising candidate blood-based biomarkers or therapeutic targets of subclinical cognitive dysfunction. Competing Interest Statement The authors have declared no competing interest. Funding Statement This work was supported by the Federal Ministry of Education and Research grant [FKZ: 01KX2230] with the title "PreBeDem - Mit Praevention und Behandlung gegen Demenz" and the Helmholtz Association under the 2023 Innovation Pool. The Rhineland Study is funded by the German Center for Neurodegenerative Diseases (DZNE). Andre Fischer received funding from the DFG priority program 1738, SFB1286, SFB 1002, by Germany's Excellence Strategy - EXC 2067/1 390729940, the ERA-Net Neuron project EPINEURODEVO and the JPND project EPI-3E. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee of the University of Bonn, Medical Faculty gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Footnotes Declarations of interest: none E-mail: Konstantinos.melas{at}dzne.de, Valentina.Talevi{at}dzne.de, Rika.Etteldorf{at}dzne.de, Santiago.Estrada{at}dzne.de, Dennis.Krueger{at}dzne.de, Tonatiuh.Pena{at}dzne.de, Ahmad.Aziz{at}dzne.de, Andre.Fischer{at}dzne.de Data Availability Access to data can be provided to scientists in accordance with the Rhineland Study's Data Use and Access Policy. Requests for additional information or to access to the Rhineland Study's datasets can be send to RS-DUAC(at)dzne.de. Abbreviations - AD - Alzheimer’s Disease - ROIs - Regions Of Interest - eTIV - estimated Total Intracranial Volume - DKT - Desikan–Killiany–Tourville - SD - Standard Deviation - WGCNA - Weighted Gene Co-Expression Analysis - fdr - false discovery rate - GWAS - Genome-Wide Association Study - MCI - Mild Cognitive Impairment - CI - Confidence Interval - HCV - Hippocampal Volume - TGF-β - transforming growth factor beta

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00